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Growth factors stimulate specific receptor tyrosine
kinases, but subsequent receptor endocytosis termi-
nates signaling. The ubiquitin ligase c-Cbl targets epi-
dermal growth factor receptors (EGFRs) to endocytosis
by tagging them with multiple ubiquitin molecules.
However, the type of ubiquitylation is unknown; whereas
polyubiquitin chains signal proteasomal degradation, ubiq-
uitin monomers control other processes. We report that in
isolation c-Cbl mediates monoubiquitylation rather than
polyubiquitylation of EGFRs. Consistent with the suffi-
ciency of monoubiquitylation, when fused to the tail of
EGFR, a single ubiquitin induces receptor endocytosis and
degradation in cells. By using receptor and ubiquitin mu-
tants, we infer that c-Cbl attaches a founder monoubiquitin
to the kinase domain of EGFR and this is complemented by
the conjugation of additional monoubiquitins. Hence, re-
ceptor tyrosine kinases are desensitized through conjuga-
tion of multiple monoubiquitins, which is distinct from
polyubiquitin-dependent proteasomal degradation.
Protein ubiquitylation has emerged as a versatile regulatory
strategy (reviewed in Ref. 1). In its best characterized role as a
signal for proteasomal degradation, productive recognition of
ubiquitylated substrates is shown to minimally require a tet-
raubiquitin chain (2). Alternatively, studies in yeast attribute
to monoubiquitylation an intrinsic capacity to target substrates
both for internalization at the plasma membrane and sorting at
multivesicular bodies toward destruction in the vacuole (re-
viewed in Ref. 3). With subsequent identification of ubiquitin
binding activities, such as the UIM,1 a rationale for ubiquitin-
dependent recognition of substrates has materialized (4–7). In
higher eukaryotic systems, ubiquitylation of cell-surface recep-
tors, likewise, correlates with their down-regulation via or-
thologous trafficking pathways that employ counterparts con-
served from yeast (8–11). Ligand-activated ubiquitylation of
EGFR, as well as other RTKs, is mediated by c-Cbl (12–14).
Whether or not EGFR ubiquitylation is sufficient for its inter-
nalization remains an open question. Likewise, although it is
clear that each endocytosed receptor is conjugated to several
molecules of ubiquitin, it is currently unknown to which extent
branching of the EGFR-conjugated ubiquitins occurs in living
cells. Here we present evidence indicating that the action of
c-Cbl is limited to the addition of monomeric ubiquitins, and
these are sufficient for receptor endocytosis and degradation.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies—Unless indicated, reagents were pur-
chased from Sigma. E1 was from Affiniti (Mamhead, Exeter, UK), and
rabbit reticulocyte lysate from Promega (Madison, WI). The 528-IgG
antibody was isolated from hybridomas and a Fab fragment prepared
and labeled with Cy3. An antibody to EGFR was from Alexis (San
Diego, CA). Anti-EEA1 mouse antibody was from Transduction Labo-
ratories (Lexington, KY). Fluorescently labeled antibodies were pur-
chased from Jackson ImmunoResearch (West Grove, PA).
Construction of Expression Vectors—A plasmid encoding a truncated
EGFR (EGFR-C) was prepared by introducing a STOP codon after
amino acid 1087. The EGFR-C4R mutant was generated by site-directed
mutagenesis. Vectors expressing EGFR::Ub chimeras were prepared by
overlap extension PCR and mutations introduced. HA-tagged ubiquitin,
either WT or K0, was subcloned into pEFIRES. Bacterial expression
vectors for wild type (His)6HA-Ub and (His)6HA-Ub-K0 were obtained by
subcloning into the pET28 plasmid (Novagen). Recombinant ubiquitins
were subsequently affinity-purified on Ni2-conjugated agarose beads.
Transient Transfection, Immunoprecipitation, and Immunoblot-
ting—Transfections were carried out using 1 g of DNA of each expres-
sion vector, and the total amount of DNA normalized with the respec-
tive empty plasmid. Cells were assayed 48 h after transfection. Whole
cell lysates were analyzed by SDS-PAGE, either directly or after im-
munoprecipitation, and protein bands detected with an enhanced
chemiluminescence reagent.
In Vitro Ubiquitylation Assay—Receptor immunoprecipitates were
extensively washed and resuspended in ubiquitylation buffer (40 mM
Tris-HCl (pH 7.5), 5 mM MgCl2, and 2 mM dithiothreitol) supplemented
with 2 mM ATP, and containing either rabbit reticulocyte lysate (1 l) or
recombinant E1 (0.1 g) and E2 (UbcH5C; 7 l of crude bacterial
extract). Wild type or mutant (His)6HA-tagged ubiquitin (0.5 g) and
GST-Cbl (0.1 g) were added as indicated. Reaction mixtures were
incubated for 1 h at 30 °C.
Immunofluorescence—Cy3-labeled Fab (20 g/ml) was incubated
with cells at 4 °C for 90 min. Thereafter, cells were transferred to 37 °C
for the indicated time intervals before fixation and visualization. Alter-
natively, paraformaldehyde-fixed cells were permeabilized for 10 min at
22 °C with phosphate-buffered saline containing 1% albumin and 0.2%
Triton X-100. For labeling, cells were incubated for 1 h with an anti-
EGFR antibody and after extensive washes incubated for an additional
hour with a Cy3-conjugated donkey anti-mouse F(ab)2. Alternatively,
coverslips were co-incubated with monoclonal anti-HA and anti-EEA1
antibodies, washed thoroughly, and incubated with a Cy3-conjugated
donkey anti-rat F(ab)2 and a Cy2-conjugated donkey anti-mouse F(ab)2.
RESULTS
In Cells c-Cbl Promotes Conjugation of Several Ubiquitins to
Each Receptor Molecule, but in Isolation It Appends Monomeric
Ubiquitins to EGFRs—In line with previous reports, when
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co-expressed with EGFR in CHO cells, c-Cbl destabilized the
receptor and enhanced receptor ubiquitylation (Fig. 1A). When
immunoblotted, the destabilized EGF-activated receptors ex-
hibited a ladder of bands representing molecules differing in
the number of conjugated ubiquitins. This stoichiometric
multiplicity can be attributed to conjugation of either a ubiq-
uitin polymer (henceforth, polyubiquitylation), many mono-
neric ubiquitins attached to several receptor’s lysines (hence-
forth, multiubiquitylation), or a combination of mono- and
polyubiquitins.
Polymerization of ubiquitin on a substrate utilizes certain
lysines as branching sites (reviewed in Ref. 1). Therefore, to
determine whether c-Cbl possesses mono- or polyubiquitylating
activity, we compared the in vitro modifying capacity of wild
type ubiquitin (WT-Ub) with that of Ub-K0 that, by definition,
is unable to form polymeric chains. Both forms were expressed
in bacteria and included as the sole source of ubiquitin in
reconstituted reactions containing an isolated EGFR. Surpris-
ingly, upon co-incubation with a bacterially expressed c-Cbl,
both WT-Ub and Ub-K0 reproduced similar patterns that, ac-
cording to the observed molecular shift, corresponded primarily
to a monoubiquitylated EGFR (Fig. 1B). Hence, the results
suggest that c-Cbl is equipped with an intrinsic monoubiquity-
lating, rather than polyubiquitylating, activity.
An Internalization-defective Mutant of EGFR Acquires Rapid
Endocytosis and Degradation When Fused to a Single Ubiq-
uitin—We predicted that once EGFR is tagged by a single molecule
of ubiquitin, it will be sorted for endocytosis even when coupling to
c-Cbl is not permitted. To test this prediction we utilized an inter-
nalization-defective mutant of EGFR, incapable of direct c-Cbl
binding (EGFR-Y1045F (15)). A single copy of ubiquitin was fused
to the carboxyl terminus of Y1045F-EGFR, but to prevent forma-
tion of covalent adducts, we replaced the terminal glycine (Ub-
G76), or both glycine 75 and glycine 76 (Ub-2GA) with alanines.
Cell-surface biotinylation assays confirmed maturation and deliv-
ery of both parental and chimeric receptor forms to the plasma
membrane (Fig. 2A). In unstimulated cells EGFR-Y1045F is not
ubiquitylated (15) and, consistent with previous studies, was found
predominantly at the plasma membrane (Fig. 2B). In contrast,
EGFR-Y1045F::Ub-G76A localized primarily to structures resem-
bling endosomes. Indeed, co-staining of EGFR-Y1045F::Ub-G76A
and the early endosomal marker, EEA1 (16), revealed a highly
significant degree of co-localization (Fig. 2C).
FIG. 1. In cells c-Cbl promotes conjugation of several ubiquit-
ins to each EGFR molecule, but in isolation only monomers of
ubiquitin are conjugated by c-Cbl. A, CHO cells expressing EGFR,
HA-Ub, and c-Cbl, as indicated, were incubated without or with EGF
(100 ng/ml) for 15 min at 37 °C, and cell lysates were analyzed with the
indicated antibodies. B, EGFR isolated from untreated A431 cells was
subjected to an in vitro ubiquitylation in the presence of E1 and E2
(UbcH5C), together with (His)6HA-Ub, WT or K0, and GST-Cbl, as
indicated. pTyr, phosphotyrosine; IB, immunoblotting; Ab, antibody; IP,
immunoprecipitation.
FIG. 2. Covalently attached monou-
biquitin is sufficient to promote endo-
cytosis and degradation of EGFR. A:
top, representation of EGFR-Y1045F::Ub;
bottom, EGFR-expressing CHO cells were
surface-biotinylated on ice and analyzed
with the indicated antibodies. B, EGFR-
expressing CHO cells were fixed, permeabi-
lized, and incubated with an anti-EGFR an-
tibody, followed by a Cy3-labeled secondary
antibody. C, cells expressing EGFR-
Y1045F::Ub-G76A were fixed, permeabi-
lized, and co-incubated with antibodies
against EEA1 and HA. Secondary fluores-
cent antibodies were used for detection. D,
HeLa cells expressing the indicated EGFR
forms were preincubated for 90 min on ice
with a Cy3-labeled 528-Fab. Subsequently,
cells were incubated at 37 °C for the indi-
cated intervals, fixed, and analyzed. E, CHO
cells expressing EGFR-Y1045F (circles) or
EGFR-Y1045F::Ub-G76A (squares) were
subjected to metabolic labeling with 35S-
labeled amino acids for 12 h. EGFR was
immunoprecipitated following the indicated
chase intervals. Shown are average decay
curves and an autoradiogram of a represent-
ative experiment. IB, immunoblotting; IP,
immunoprecipitation; ECD, extracellular
domain; TM, transmembrane domain; TK,
tyrosine kinase; C-ter, carboxyl-terminal;
HRP, horseradish peroxidase; Ab, antibody.
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To track endocytosis of EGFR and yet avoid ligand- or anti-
body-induced internalization, we used a fluorescently labeled
monovalent fragment of an anti-EGFR antibody (528-Fab).
First, this analysis left out the possibility that EGFR::Ub chi-
meras, like some lysosomal enzymes (5, 6), reach endosomal
structures directly from the biosynthetic pathway. Second,
when cells were preincubated on ice with 528-Fab and then
transferred to 37 °C, we noted different kinetics of internaliza-
tion; unlike EGFR-Y1045F, which remained largely at the cell
surface and started appearing in intracellular vesicles only
after 20 min (Fig. 2D), some chimeric receptors translocated
into endosomes already 5 min after transfer to 37 °C, and their
endocytosis peaked at 10 min. In line with different endocytic
behavior, metabolic labeling showed the chimeras to be de-
graded considerably more rapidly than EGFR-Y1045F in the
absence of EGF (Fig. 2E). These results imply that monoubiq-
uitylation is sufficient for internalization of EGFR, and to-
gether with the data presented in Fig. 1, they suggest that
Cbl-mediated tagging of monomeric ubiquitins sorts active re-
ceptors to degradation.
Decoration of EGFR with Monoubiquitins, Not Polyubiquit-
ins, Is Sufficient for Ligand-induced Receptor Degradation—
The observed difference between c-Cbl’s activity in isolation
(monoubiquitylation) and in cells (multi- or polyubiquitylation)
implies recruitment of a collaborating activity. Hence, we com-
pared ubiquitylation of EGFR in the presence of recombinant
E1 and E2 or a crude mixture of cellular factors (namely,
reticulocyte lysate). Analysis under electrophoretic conditions
aimed at resolving ubiquitylated species detected a signifi-
cantly higher ladder of EGFR when incubated with c-Cbl and
reticulocyte lysate (Fig. 3A). The smeary pattern was particu-
larly detectable by anti-phosphotyrosine antibodies, indicating
selectivity to active receptors. Furthermore, replacing wild
type ubiquitin with a Ub-K0 did not change the ubiquity-
lation pattern (Fig. 3B). Conceivably, Cbl-induced monoubiqui-
tylation of phosphorylated EGFRs is followed by recruit-
ment of unknown effectors, which mediate additional
monoubiquitylation.
To resolve whether EGFR ubiquitylation in cells entails mo-
nomeric or polymeric ubiquitin, we utilized a series of ubiquitin
mutants with individual lysine-to-arginine substitutions at
known sites for chain branching in vivo (lysines 11, 29, 48, and
63 (1, 17)). Preliminary analyses indicated that the ectopic
ubiquitin attained a 10-fold excess over the endogenous mol-
ecule 18 h after transfection. Under these conditions all four
mutants, namely K11R, K29R, K48R, and K63R, reconstituted
similar patterns of ligand-induced EGFR ubiquitylation as
wild-type ubiquitin (Fig. 3C and data not shown). Furthermore,
no mutant inhibited or delayed EGF-induced degradation of
EGFR, and hence, none of the tested lysines appears to be
FIG. 3. EGFR undergoes multiubiquitylation, not polyubiqui-
tylation. A, EGFR immunoprecipitates from untreated A431 cells were
ubiquitylated in vitro in the presence of either recombinant E1 and E2,
or reticulocyte lysate (RL), together with (His)6HA-Ub and GST-Cbl, as
indicated. Reaction mixtures were incubated at 30 °C for 60 min before
immunoblotting. B, in vitro ubiquitylation of isolated EGFRs was per-
formed in the presence of reticulocyte lysate. GST-Cbl and HA-Ub were
added as indicated. C: top, representation of all lysines of ubiquitin.
Forward (lysine-to-arginine) and add-back (arginine-to-lysine) mutants
are depicted. Bottom, CHO cells expressing c-Cbl and EGFR, along with
the indicated forms of HA-Ub, were incubated without or with EGF for
15 min at 37 °C, and cell lysates were analyzed as indicated. pTyr,
phosphotyrosine; IB, immunoblotting; IP, immunoprecipitation; Ab,
antibody.
FIG. 4. Cbl-induced ubiquitylation impinges on the tyrosine
kinase domain of EGFR. A, schematic representation of EGFR-
C4R, a truncated receptor (residues 1–1087) in which lysine residues
not included within the tyrosine kinase (TK) domain were mutated. B,
EGFRs derived from unstimulated transfected HEK-293T cells were
subjected to ubiquitylation in vitro in the presence of recombinant E1
and E2. C, CHO cells expressing HA-Ub, c-Cbl, and either wild type
EGFR (WT) or the truncation mutant (C4R), were analyzed as indi-
cated. pTyr, phosphotyrosine; IB, immunoblotting; IP, immunoprecipi-
tation; Ab, antibody.
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involved in ubiquitin chain branching. To consolidate this con-
clusion, reciprocal experiments were performed using Ub-K0.
When overexpressed, this mutant acts as a terminator of ubiq-
uitin polymerization. However, Ub-K0 expressing cells effec-
tively incorporated the mutant form of ubiquitin into EGFR
molecules, which retained their normal ubiquitylation pattern
(Fig. 3C). As expected, when tested in conjunction with -cate-
nin, a well characterized substrate of polyubiquitylation and
proteasomal degradation, Ub-K0 abolished the typical ladder of
ubiquitylated -catenin (data not shown). Moreover, add-back
mutants derived from Ub-K0 underwent comparable conjuga-
tion to EGFR, and even though they limited the extent of
receptor degradation compared with WT-Ub, none extended or
enhanced the ladder of ubiquitylated EGFRs (Fig. 3C and data
not shown). In conclusion, because all lysine mutants of ubiq-
uitin coherently generated a pattern consistent with multiu-
biquitylation, these results reinforce a role for monoubiquitin
in sorting EGFR to endocytosis.
Multiubiquitylation Confined to the Kinase Domain of EGFR
Is Sufficient for Receptor Degradation—The results presented
suggest that multiubiquitylation of EGFR is preceded by a
monoubiquitylating event. In an attempt to map the putative
site, we generated a truncation mutant containing lysines only
within its kinase domain (EGFR-C4R; Fig. 4A), a region es-
sential for c-Cbl recruitment (12). In vitro, EGFR-C4R, like
wild-type EGFR, underwent c-Cbl-mediated monoubiquityla-
tion (Fig. 4B), raising the possibility that the kinase domain
may be specifically targeted by c-Cbl. Testing EGFR-C4R in
living CHO cells lent support to this assignment. First, the
EGFR-C4R mutant, like the wild type receptor, underwent
weak monoubiquitylation in unstimulated cells (Fig. 4C). Fur-
thermore, regardless of its smaller number of potential accep-
tor sites, EGFR-C4R underwent EGF-induced multiubiquity-
lation, and its degradation was accelerated by EGF and c-Cbl
(Fig. 4C). Subsequent kinetic experiments, which are not pre-
sented, showed that both forms of EGFR underwent compara-
bly rapid ubiquitylation, in support of the possibility that a
kinase domain lysine serves as a founder monoubiquitylation
site.
DISCUSSION
Fusion of a single ubiquitin to different integral membrane
proteins led to the conclusion that ubiquitylation controls cargo
endocytosis (11, 18, 19). Our work extends this notion to RTKs
and envisages a stepwise process leading to the termination of
growth factor signaling: ligand-induced phosphorylation of
EGFR recruits c-Cbl (15), and then an E2 molecule, which is
physically attached to c-Cbl, discharges its thioester-bonded
ubiquitin at a lysine residue, likely located within the kinase
domain of EGFR (Fig. 4). Because in isolation c-Cbl conjugates
monomeric ubiquitins (Fig. 1B), and covalent attachment of a
single ubiquitin drives endocytosis of an internalization-defec-
tive receptor (Fig. 2), we propose that the founder ubiquitin
undergoes no branching, and its conjugation instigates sorting
of ubiquitylated EGFRs. Predictably, the sorting mechanism
involves adaptors bearing UIMs, such as Eps15 and epsin (7,
10). Conceivably, while at the cell surface or en route to the
lysosome, EGFR is further decorated with additional mono-
mers of ubiquitin. The mechanism of this secondary multiubiq-
uitylation step remains unknown.
Considering the ability of a single ubiquitin to drive receptor
endocytosis, it is worthwhile asking why EGFR is multi-ubiq-
uitylated? For one, multiple monomers may confer resistance
to inhibition by deubiquitylating enzymes. Alternatively, suc-
cessive monoubiquitylation may increase the avidity of EGFR
binding to adaptors like Eps15 (10). Last, multiubiquitylation
rather than polyubiquitylation may confer to EGFR refractori-
ness to the 26S proteasome. Notably, both endocytic adaptors
(20) and one of the ubiquitin-binding proteasomal subunits (21)
utilize UIMs to recognize their cargoes and substrates. Hence,
in the endosomal pathway, the intrinsic inability of c-Cbl to
attach more than one ubiquitin to EGFR and to subsequently
polymerize ubiquitin may suffice the endocytic machinery
while evading degradation by proteasomes. Consistent with a
mechanism that evades the proteasome, c-Cbl undergoes self-
ubiquitylation with no associated proteasomal degradation
(22). Hence, the E3 ligase activity of c-Cbl may be confined to
monoubiquitylation. This issue and the possibility that other
E3 ligases complement the action of c-Cbl toward the EGFR are
matters for future investigation.
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